Li-Ming Gan is a specialist in non-invasive cardiology with broad clinical skills in cardiovascular diagnostics.

Since 2009, he has been professor in translational cardiovascular research and drug discovery at Sahlgrenska University Hospital in Göteborg, Sweden. Li-Ming actively runs academic research in the field of cardiovascular phenotyping of patients with ischemic heart disease and heart failure, as well as the development and validation of preclinical translational animal disease models.

Li-Ming joined AstraZeneca 12 years ago, where he established a preclinical translational disease platform in atherosclerosis, cardiovascular (CV) disease and heart failure area during his first five years. In 2007, Li-Ming was appointed as Disease Area Portfolio Leader and later as Science Director, responsible for bringing new drug projects into the pipeline. Between 2011 and 2013, he was CV Translational Science Director to help transfer early studies into the human setting. Here, he developed novel biomarkers and performed explorative human studies to identify and validate new drug targets.

Li-Ming is currently Vice President of Early Clinical Development in CVRM and is responsible for all clinical activities, including early explorative human experimental work, human target validation and clinical trials up to phase 2b in the cardiovascular space.

The environment has changed dramatically in the last two years, we are much more science focused. We are almost like a university today.

Li-Ming Gan Vice President, Early Clinical Development, Research and Early Development, CVRM, BioPharmaceuticals R&D


Searching for a cure for Heart Failure


Investigating cardiac regeneration to develop innovative therapies against heart failure using novel treatment modalities e.g. modified RNA


Building a unique imaging translational platform for proof of concept work from animals to humans


An innovative study using unique imaging capability to proof the adenosine mode of action of ticagrelor in man

  Featured publications

Cardiometabolic risk loci share downstream cis- and trans-gene regulation across tissues and diseases

Cardiometabolic risk loci share downstream cis- and trans-gene regulation across tissues and diseases. Li-Ming Gan, Christer Betsholtz. Science  19 Aug 2016: Vol. 353, Issue 6301, pp. 827-830

Non-invasive imaging of atherosclerosis in mice

Non-invasive real-time imaging of atherosclerosis in mice using ultrasound biomicroscopy. L Gan, J Grönros, U Hägg, J Wikström, C Theodoropoulos, P Friberg, Fritsche-Danielson R. Atherosclerosis 2007 190 (2), 313-320

Translational coronary flow imaging in mice

Functional and morphologic imaging of coronary atherosclerosis in living mice using high-resolution color Doppler echocardiography and ultrasound biomicroscopy. J Wikström, J Grönros, G Bergström, L Gan. Journal of the American College of Cardiology 2005 46 (4), 720-727

Proving the adenosine mode of action of ticagrelor.

Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans. Wittfeldt A, Emanuelsson H, Brandrup-Wognsen G, van Giezen JJ, Jonasson J, Nylander S, Gan LM. J Am Coll Cardiol. 2013: 61(7):723-7. doi: 10.1016/j.jacc.2012.11.032.

I am very stimulated to combine academic work with focused pharmaceutical research, to discover novel therapies that treat human diseases with great unmet medical need.

Li-Ming Gan